Gastrointestinal (GI) syndromes, such as diarrhea, abdominal pain, vomiting, and loss of appetite are commonly seen in patients with coronavirus 2019 (COVID-19). However, the pathophysiological mechanism connecting these gastrointestinal symptoms to coronavirus 2 (SARS-CoV-2) infection remains elusive.

Convalescent plasma therapy in the treatment of COVID-19 patients is considered and evaluated as a potential new therapy to increase the tools for doctors to treat patients, especially those with severe disease progression.